In summary, the findings of this study indicated no significant differences in QOL among RA patients treated with TCZ versus other anti-TNF mAbs, such as ADA and ETA, as evaluated by the EQ-5D-5L questionnaire and VAS score. The gene discussed is ADA; the disease is rheumatoid arthritis.